Once a formulation has been established in preclinical studies and is proven for effective administration, translation to a lipid-based drug formulation first-in-human (FIH) studies requires further consideration and can pose new challenges.
TORONTO (PRWEB)
December 19, 2022
A high proportion of new drug candidates never reach market due to poor solubility, which limits their potential for absorption. As such, the solubility and permeability of an active pharmaceutical ingredient (API) are the driving forces behind bioavailability. In order to avoid development challenges and delays, it is critical to fully explore these parameters when developing formulations to enhance and maximise oral bioavailability. Lipid-based drug delivery systems offer a way to effectively deliver poorly soluble or bioavailable drugs in both preclinical and human studies. The physicochemical characteristics of the API determine if lipid delivery is an appropriate approach for dosage form design.
Understanding how lipid molecules are classified, in what circumstances they can be utilized and how to design an effective lipid-based drug delivery formulation is complex. Once a formulation has been established in preclinical studies and is proven for effective administration, translation to a lipid-based drug formulation first-in-human (FIH) studies requires further consideration and can pose new challenges.
This webinar will cover the rationale for dosage form design of lipid-based formulations to ensure successful project delivery, including: Considerations for why lipid approaches are successful and appropriate for assessment; The theoretical basis for classification of lipid-based systems; Design and characterisation of lipid-based systems; Associated analytics required to ensure product robustness and clinical safety; And examples of challenges associated with API recovery from complex matrices.
As products translate to human studies, it is essential to consider the requirements of a target product profile, with particular focus on aiding patient compliance. The featured speakers will share examples on approaching product design and scale up for various dosage forms and case studies to show the various project stages and duration of activities associated with developing successful formulations for FIH studies.
Register to learn about improving dosage form design in lipid-based drug delivery systems, from preclinical to first-in-human studies.
Join experts from SGS Quay Pharma, Dr. Mike Frodsham, Chief Technical Officer; and Rober Habashy, MSc, Group Technical Manager, for the live webinar on Tuesday, January 10, 2023, at 11am EST (4pm GMT/UK).
For more information, or to register for this event, visit Lipid-Based Drug Delivery: Dosage Form Design from Preclinical to First-in-Human.
ABOUT XTALKS
Xtalks, powered by Honeycomb Worldwide Inc., is a leading provider of educational webinars to the global life science, food and medical device community. Every year, thousands of industry practitioners (from life science, food and medical device companies, private & academic research institutions, healthcare centers, etc.) turn to Xtalks for access to quality content. Xtalks helps Life Science professionals stay current with industry developments, trends and regulations. Xtalks webinars also provide perspectives on key issues from top industry thought leaders and service providers.
To learn more about Xtalks visit http://xtalks.com
For information about hosting a webinar visit http://xtalks.com/why-host-a-webinar/
Contact:
Vera Kovacevic
Tel: +1 (416) 977-6555 x371
Email: vkovacevic@xtalks.com
Share article on social media or email: